Travere Therapeutics, Inc. Income Statement
TVTX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Travere Therapeutics, Inc. reported $491M in revenue and $26M in net loss for FY2025. Revenue has grown at a 29.7% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $175.3M | $164.2M | $154.9M | $133.6M | $99.9M | $28.2M | $99.9M | $28.2M | $0 | - | $0 |
| Cost of Revenue | $10.3M | $7.7M | $11.4M | $4.4M | $5.2M | $5.5M | $3.6M | $4.6M | $2.2M | $571.0K | $2.2M | $571.0K | $0 | - | - |
| SG&A Expense | $337.2M | $264.1M | $265.5M | $197.5M | $129.0M | $103.7M | $101.3M | $91.9M | $79.5M | $59.6M | $79.5M | $59.6M | $17.7M | $29.6M | $63.8K |
| R&D Expense | $206.0M | $217.5M | $245.0M | $7.5M | $141.0M | $123.8M | $78.2M | $70.8M | $50.4M | $47.8M | $50.4M | $47.8M | $7.1M | $662.5K | $353.0K |
| Operating Income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$137.4M | -$80.0M | -$53.8M | -$58.2M | -$50.7M | -$79.8M | -$50.7M | -$79.8M | -$24.8M | -$30.3M | - |
| Interest Expense | - | - | $11.3M | $11.0M | $18.8M | $9.8M | $4.4M | $4.7M | $7.7M | $7.4M | $7.7M | $7.4M | $0 | $84.1K | - |
| Income Tax | $988.0K | $120.0K | $223.0K | $313.0K | -$21.0K | $811.0K | $1.4M | -$9.7M | -$11.8M | -$2.5M | -$11.8M | -$2.5M | $76.0K | - | - |
| Net Income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$146.4M | -$102.7M | -$59.7M | -$47.9M | $117.2M | -$110.9M | $117.2M | -$110.9M | -$34.6M | -$30.3M | -$3.3M |
| EPS (Basic) | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | - | - | -$1.29 | $3.49 | -$4.43 | -$2.44 | -$3.25 | -$2.44 | - | - |
| EPS (Diluted) | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.17 | -$4.43 | -$2.44 | -$3.25 | -$2.44 | - | - |
| Shares Outstanding | 87.5M | 75.4M | 64.3M | 62.5M | 52.2M | 43.1M | 41.4M | 39.4M | 37.9M | 36.5M | 26.0M | 18.4M | 14.2M | 3.7M | 106.7K |
| Operating Margin | -12.8% | -138.9% | -267.2% | -292.2% | -78.3% | -48.7% | -34.7% | -43.6% | -50.8% | -283.0% | -50.8% | -283.0% | - | - | - |
| Profit Margin | -5.2% | -137.9% | -76.7% | -254.4% | -83.5% | -62.5% | -38.6% | -35.9% | 117.4% | -393.4% | 117.4% | -393.4% | - | - | - |